■母体中枢亲神经性药物暴露后新生儿发病率的评估。
■2018年至2021年CND后新生儿的回顾性单中心III级新生儿学队列分析。对照组在产科病房照顾没有CND的母亲所生的新生儿。
■CND新生儿需要更频繁的治疗[OR23(95%CI:7.8-62);RR14(95%CI:5.4-37);p<0.01]。CND后新生儿的Apgar评分较低，LM1[CND8.1;CG8.6;p<0.05];LM5[CND9;CG9.7;p<0.01];LM10[CND9.6;CG9.9;p<0.05]。24h内首发症状占95.35%(平均3.3h)。CND组显示早产明显更频繁[OR3.5;RR3.2;p<0.05]，尤其是累积的多种症状[OR9.4;RR6.6;p<0.01]，但与母亲多次用药无关（p=0.3）。
■暴露于CND的新生儿产后治疗的风险增加，通常是由于多种症状。应连续监测新生儿至少24小时。
Evaluation of neonatal morbidity after maternal central neurotropic drug exposure.
Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND cared for at the maternity ward.
Significantly more frequent therapy need of neonates with CND [OR 23 (95% CI: 7.8-62); RR 14 (95% CI: 5.4-37); p < 0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p < 0.05]; LM 5 [CND 9; CG 9.7; p < 0.01]; LM 10 [CND 9.6; CG 9.9; p < 0.05]. The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p < 0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p < 0.01] but no correlation to multiple maternal medication use (p = 0.3).
Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be continuously monitored for at least 24 h.
